mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. - Wikidata - awgldk - TriplyDB

mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.

mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.

http://www.wikidata.org/entity/Q35003274

about

The critical role of Akt in cardiovascular function Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method Baicalin inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via the AKT/HIF-1α/p27-associated pathway mTORC2 is required for proliferation and survival of TSC2-null cells.A cell permeable peptide targeting the intracellular loop 2 of endothelin B receptor reduces pulmonary hypertension in a hypoxic rat model Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension.Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK.A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension.Rapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease.PDGF enhances store-operated Ca2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells.Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells.A novel nontoxic inhibitor of the activation of NADPH oxidase reduces reactive oxygen species production in mouse lung.mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells Adenosine monophosphate-activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system.Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.Emerging role of selective autophagy in human diseases.Autophagy in lung disease pathogenesis and therapeutics.Mesoglycan attenuates VSMC proliferation through activation of AMP-activated protein kinase and mTOR.Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.Biocompatible reactive oxygen species (ROS)-responsive nanoparticles as superior drug delivery vehicles.Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway.mTOR-Notch3 signaling mediates pulmonary hypertension in hypoxia-exposed neonatal rats independent of changes in autophagy.TOR signaling couples oxygen sensing to lifespan in C. elegans.Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells.Suppression of endothelial PGC-1α is associated with hypoxia-induced endothelial dysfunction and provides a new therapeutic target in pulmonary arterial hypertension.Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway.Emerging Therapeutics in Pulmonary Hypertension.Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.mTOR: A Key to Both Pulmonary Vessel Remodeling and Right Ventricular Function in Pulmonary Arterial Hypertension?mTORC1 is involved in hypoxia-induced pulmonary hypertension through the activation of Notch3.Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.

P2860

Q28083829-EDC955B6-37AE-4345-ABE9-1135337FA706 Q33587163-3CDF5CB9-DC07-41F9-9080-B64F419A70E7 Q33755731-D28A2F31-C0E4-47DB-911E-E62530AACE31 Q34177457-5CF24508-2FCD-4645-B84A-A2E902792DB8 Q35060505-1C857EBC-855C-4CE8-9F3D-D137C4ED5B3A Q35115837-734BE12D-58A8-4AE7-A68C-CBDFE1E26ACF Q35533008-3B963B73-557B-4B3A-83BF-5191113C489F Q35676912-3231A2FF-F2D1-41D8-9491-0EDDFEB829E5 Q35789958-9AB62AA1-A6FF-4740-A899-544533FB56CF Q35895524-03B8EF8A-783E-4705-BB9F-46109634D416 Q35916851-721B37E9-E6E0-4E10-A400-1D1D47BB3F2C Q36535586-9CAFE9C7-B44A-4743-9AFA-F457AADE80D7 Q36776546-3DE4F3CC-A463-4987-904B-7569ABC30054 Q36788720-942F7AB3-96E5-439D-A7C4-1974F129E35C Q36990317-D056808F-02D3-4A64-B8AB-3C5C86117C06 Q36996364-5530A4EC-8401-4873-85E7-82C54CEA7C35 Q37139375-078FA134-B010-424F-838E-7A88B5EF8319 Q37297940-6B55B0D9-29B2-49E1-B74C-3E3E7DE8A520 Q37510481-4CEC4657-EACA-4F2B-AA48-9B0411FF0729 Q37670612-3DDC10FA-115D-4AAF-85CB-362DCBAD6C68 Q38270177-D31CD7BF-BD32-496B-92F1-1A8781121BE6 Q38330890-41F27317-2103-4204-9C1C-97B464D8BE72 Q38368556-68B0C274-4707-4417-A6B8-5FE281F9CDEE Q38692684-F926189E-2AF6-43AA-9643-F357E3364016 Q38963794-9438D8A8-4CEE-447F-B332-A8EA09296251 Q39279796-D10499B2-4CDF-4396-A238-61E897A37DC2 Q39817890-CFF3EDE8-C58C-4DA8-9B08-87D9CEA9CC8B Q41463478-E5F3C66E-9840-4BFC-B629-880BAF327488 Q41912240-EFDB7693-2119-4581-84BF-B39AE96EBF9D Q42775625-7EC4B90F-9F85-42EF-BAC6-FC943B23EF89 Q46435567-59D05BC9-DCDD-4A6C-8E6F-D17C1B245910 Q46562780-BFA0C48C-DA3A-4017-930F-9AF2EEB7BF48 Q47160619-B5BFCFAB-FB43-460A-AC9E-7A55B53808DD Q47700134-A71E9BAD-2716-4D57-9AC8-8AADF6DFD07F Q47966441-2D669E1E-A99A-4267-AB4A-F8094FD82930 Q49471057-811593C4-84A5-454D-838E-177627265A52 Q51769049-86B14A4A-1F43-4B87-B3C0-18FC105B1BAB Q54352868-4E4B4934-C8BC-4772-9C67-1A2949F30ADB Q55026570-177E85AA-1009-4613-9BB1-44E2C0966A63

P2860

mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.

http://www.wikidata.org/entity/Q35003274

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

mTOR is required for pulmonary ...... eration under chronic hypoxia.

@ast

mTOR is required for pulmonary ...... eration under chronic hypoxia.

@en

type

label

mTOR is required for pulmonary ...... eration under chronic hypoxia.

@ast

mTOR is required for pulmonary ...... eration under chronic hypoxia.

@en

prefLabel

mTOR is required for pulmonary ...... eration under chronic hypoxia.

@ast

mTOR is required for pulmonary ...... eration under chronic hypoxia.

@en

P1433

Q35003274-5A7177F9-5B52-43EB-AE04-D4DBE9A43A29

P1476

Q35003274-A02C67CD-996B-4F8C-8CA7-4B7D05C9AF33

P2093

Q35003274-056FDE3B-7131-4A7B-940F-4C165FA81F4A

Q35003274-09644659-C25E-4E2F-A3D2-4EA18973E630

Q35003274-11BE7C47-BBD2-42F3-8677-11782930543D

Q35003274-12D763C2-0EE7-4A42-A927-513ECB634A66

Q35003274-22D009AC-5965-4523-A253-977B5D5AEBB3

Q35003274-3E3D4B54-89E0-4E6D-BE0F-0D2628429520

Q35003274-62AC61D8-5059-4DC6-A2D4-6351BA5ACE3C

Q35003274-91622171-85F3-4E32-AC0E-C0DAB6172326

Q35003274-B9F3C7E6-C9B7-4F9B-A43A-62D3AD7A00EC

Q35003274-D05F290E-B22A-40AA-B317-0F20A844B0BE

P2860

Q35003274-009FB3A9-08FA-4B0D-B170-A5CFEE91C038

Q35003274-06D019E1-9D26-4B4E-B417-B2845FEC483E

Q35003274-098111A1-0E40-49DF-8D26-4F6324BC41EA

Q35003274-0EE1AD77-DB1E-45E5-AE9C-997B3DBF49B2

Q35003274-1533896B-331B-4E12-BBC3-96A4DE6215D0

Q35003274-1714667F-C640-460E-9D07-542130D614D9

Q35003274-226DB3B1-14FB-4ACA-BBEB-BC9594BF649F

Q35003274-23611AFA-7C0E-4316-91F1-1F7F05FC0994

Q35003274-25AB3C60-D358-46F8-A44B-8C0125EDC6BB

Q35003274-27A9EEE7-2394-4A1E-B949-75FF410D4433

P304

Q35003274-F8E83DD3-4A22-4806-B166-0CFDC5B437F2

P31

Q35003274-6E303E58-A0CC-4F24-A455-8387E9C57BA5

P356

Q35003274-82C18BF3-0BD5-423A-BE1A-F55E37AF5BB9

P407

Q35003274-87E7583B-19C3-44EC-9191-41BA26E550D6

P433

Q35003274-50E89A4D-918F-499E-B1EC-8F6C350B7870

P478

Q35003274-D75880DD-481D-43C8-B6B7-5B8F2EAA375D

P577

Q35003274-59A3B156-12A8-4FB3-86CE-A6F615422E04

P698

Q35003274-FEB8BB2A-FC1E-4444-8E91-6B7ADD2F1D3C

P921

Q35003274-6728AA22-B3F0-430D-A175-0AAA2E6541C0

P932

Q35003274-FEB5EB21-5176-4735-8305-65D49658613C

P356

P1433

P1476

mTOR is required for pulmonary ...... eration under chronic hypoxia.

@en

P2093

Dmitry A Goncharov

http://www.w3.org/2001/XMLSchema#string

Elena A Goncharova

http://www.w3.org/2001/XMLSchema#string

Gregory Cesarone

http://www.w3.org/2001/XMLSchema#string

Irene Khavin

http://www.w3.org/2001/XMLSchema#string

Jennifer Snow

http://www.w3.org/2001/XMLSchema#string

Kaori Ihida-Stansbury

http://www.w3.org/2001/XMLSchema#string

Peter L Jones

http://www.w3.org/2001/XMLSchema#string

Poay N Lim

http://www.w3.org/2001/XMLSchema#string

Sigrid C Veasey

http://www.w3.org/2001/XMLSchema#string

Vera P Krymskaya

http://www.w3.org/2001/XMLSchema#string

P2860

Notch3 signaling promotes the development of pulmonary arterial hypertension

Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status

Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase

mTOR and cancer: insights into a complex relationship

mTOR signaling at a glance

Updated clinical classification of pulmonary hypertension.

P304

1922-1933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.10-175018

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21368105

http://www.w3.org/2001/XMLSchema#string

P921

P932

3101038

http://www.w3.org/2001/XMLSchema#string